WASHINGTON — Supporters of a Senate-passed “right-to-try” bill that aims to help terminally ill patients gain access to experimental treatments are pushing for the House to act quickly on the measure — but key House leaders showed little interest in that push.

Sen. Ron Johnson (R-Wis.), who threatened to hold up a bipartisan and timely package of Food and Drug Administration policies in August in order to push his right-to-try legislation through the Senate, called on the House this week to pass his bill without changing a word. Any modifications in the House would force the Senate to reconsider the bill anew.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy